nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 29th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 29th, 2022 11:20AM
|
Aug 29th, 2022 11:20AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 28th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 28th, 2022 04:20AM
|
Aug 28th, 2022 04:20AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 27th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 27th, 2022 03:39AM
|
Aug 27th, 2022 03:39AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 25th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 25th, 2022 08:19AM
|
Aug 25th, 2022 08:19AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 23rd, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 23rd, 2022 10:13AM
|
Aug 23rd, 2022 10:13AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 21st, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 21st, 2022 11:56AM
|
Aug 21st, 2022 11:56AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 20th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 20th, 2022 01:32PM
|
Aug 20th, 2022 01:32PM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 19th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 19th, 2022 11:56AM
|
Aug 19th, 2022 11:56AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 18th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 18th, 2022 03:39AM
|
Aug 18th, 2022 03:39AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:alny
|
https://www.indeed.com/cmp/alnylam-pharmaceuticals
|
Aug 17th, 2022 12:00AM
|
Open
|
Alnylam Pharmaceuticals
|
|
Pharmaceutical & Biotechnology
|
Alnylam Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core focus is the development and commercialization of novel therapeutics based on RNA interference, or RNAi, for genetically defined diseases. Alnylam was founded in 2002 by Phillip Sharp, Paul Schimmel, Dave Bartel, Thomas Tuschl and Phillip Zamore.
|
|
|
|
|
|
4.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.00
|
26.00
|
4.20
|
4.10
|
3.90
|
3.80
|
4.20
|
11.00
|
About a week
|
12.00
|
MEDIUM
|
12.00
|
FAVORABLE
|
|
|
|
Aug 17th, 2022 09:18AM
|
Aug 17th, 2022 09:18AM
|
Alnylam Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|